CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Saniona AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Saniona AB
Smedeland 26B
GLOSTRUP, 2600  Denmark Ticker: SANIONSANION

Business Summary
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board JoergenDrejer 68 5/25/2022 1/1/2014
Chief Executive Officer ThomasFeldthus 63 4/30/2022 1/1/2014
Chief Financial Officer AnitaMilland 55 4/30/2022 4/30/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Initiator Pharma A/S Co/ COBIS, Ole Maaloeesvej 3 KOEBENHAVN Denmark

Business Names
Business Name
0RQJ
Initiator Pharma A/S
SANION

General Information
Number of Employees: 23 (As of 12/31/2023)
Outstanding Shares: 132,529,086 (As of 1/17/2024)
Shareholders: 10,145
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024